Robert L. Comis: In Memoriam

por Bertagnolli, Monica M., O’Dwyer, Peter J.
Publicado 2017

CCL25/CCR9 Interactions Regulate Large Intestinal Inflammation in a Murine Model of Acute Colitis

por Wurbel, Marc-Andre, McIntire, Maria G., Dwyer, Peter, Fiebiger, Edda
Publicado 2011

A Soluble Form of the High Affinity IgE Receptor, Fc-Epsilon-RI, Circulates in Human Serum

por Dehlink, Eleonora, Platzer, Barbara, Baker, Alexandra H., LaRosa, Jessica, Pardo, Michael, Dwyer, Peter, Yen, Elizabeth H., Szépfalusi, Zsolt, Nurko, Samuel, Fiebiger, Edda
Publicado 2011

Dielectrophoretic Capture and Genetic Analysis of Single Neuroblastoma Tumor Cells

por Carpenter, Erica L., Rader, JulieAnn, Ruden, Jacob, Rappaport, Eric F., Hunter, Kristen N., Hallberg, Paul L., Krytska, Kate, O’Dwyer, Peter J., Mosse, Yael P.
Publicado 2014

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Ca...

por Goldman, Jonathan W., Waterhouse, David M., George, Ben, O'Dwyer, Peter J., Bhore, Rafia, Banerjee, Sibabrata, Lyons, Larry, Louis, Chrystal U., Ong, Teng Jin, Kelly, Karen
Publicado 2019

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation

por Wattenberg, Max M., Asch, Daniella, Yu, Shun, O’Dwyer, Peter J., Domchek, Susan M., Nathanson, Katherine L., Rosen, Mark A., Beatty, Gregory L., Siegelman, Evan S., Reiss, Kim A.
Publicado 2019

E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors

por Lubner, Sam, Feng, Yang, Mulcahy, Mary, O'Dwyer, Peter, Giang, Guang‐Yu, Hinshaw, J. Louis, Deming, Dustin, Klein, Leonard, Teitelbaum, Ursina, Payne, Jennifer, Engstrom, Paul, Stella, Philip, Meropol, Neal, Benson, Al
Publicado 2018

Early treatment-related neutropenia predicts response to palbociclib

por McAndrew, Nicholas P., Dickson, Mark A., Clark, Amy S., Troxel, Andrea B., O’Hara, Mark H., Colameco, Christopher, Gallager, Maryann, Gramlich, Kristi, Zafman, Kelly, Vaughn, David, Schwartz, Gary K., O’Dwyer, Peter J., DeMichele, Angela
Publicado 2020

THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma

por Gimotty, Phyllis A., Till, Jacob E., Udgata, Shirsa, Takenaka, Naomi, Yee, Stephanie S., LaRiviere, Michael J., O’Hara, Mark H., Reiss, Kim A., O'Dwyer, Peter, Katona, Bryson W., Herman, Daniel, Carpenter, Erica L., Zaret, Kenneth S.
Publicado 2021

Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma

por Gimotty, Phyllis A., Till, Jacob E., Udgata, Shirsa, Takenaka, Naomi, Yee, Stephanie S., LaRiviere, Michael J., O’Hara, Mark H., Reiss, Kim A., O’Dwyer, Peter, Katona, Bryson W., Herman, Daniel, Carpenter, Erica L., Zaret, Kenneth S.
Publicado 2022

Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

por El-Khoueiry, Anthony B., Clarke, James, Neff, Tobias, Crossman, Tim, Ratia, Nirav, Rathi, Chetan, Noto, Paul, Tarkar, Aarti, Garrido-Laguna, Ignacio, Calvo, Emiliano, Rodón, Jordi, Tran, Ben, O’Dwyer, Peter J., Cuker, Adam, Abdul Razak, Albiruni R.
Publicado 2023

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer

por Karasic, Thomas B, Brown, Timothy J, Schneider, Charles, Teitelbaum, Ursina R, Reiss, Kim A, Mitchell, Tara C, Massa, Ryan C, O’Hara, Mark H, DiCicco, Lisa, Garcia-Marcano, Luis, Amaravadi, Ravi K, O’Dwyer, Peter J
Publicado 2022

Clinical study of genomic drivers in pancreatic ductal adenocarcinoma

por Barrett, Michael T, Deiotte, Ray, Lenkiewicz, Elizabeth, Malasi, Smriti, Holley, Tara, Evers, Lisa, Posner, Richard G, Jones, Timothy, Han, Haiyong, Sausen, Mark, Velculescu, Victor E, Drebin, Jeffrey, O'Dwyer, Peter, Jameson, Gayle, Ramanathan, Ramesh K, Von Hoff, Daniel D
Publicado 2017

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

por Kopetz, Scott, Desai, Jayesh, Chan, Emily, Hecht, Joel Randolph, O'Dwyer, Peter J., Maru, Dipen, Morris, Van, Janku, Filip, Dasari, Arvind, Chung, Woonbook, Issa, Jean-Pierre J., Gibbs, Peter, James, Brian, Powis, Garth, Nolop, Keith B., Bhattacharya, Suman, Saltz, Leonard
Publicado 2015

A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence

por Heumann, Thatcher R., Baretti, Marina, Sugar, Elizabeth A., Durham, Jennifer N., Linden, Sheila, Lopez-Vidal, Tamara Y., Leatherman, James, Cope, Leslie, Sharma, Anup, Weekes, Colin D., O’Dwyer, Peter J., Reiss, Kim A., Monga, Dulabh K., Ahuja, Nita, Azad, Nilofer S.
Publicado 2022

Strong Signature of Natural Selection within an FHIT Intron Implicated in Prostate Cancer Risk

por Ding, Yan, Larson, Garrett, Rivas, Guillermo, Lundberg, Cathryn, Geller, Louis, Ouyang, Ching, Weitzel, Jeffrey, Archambeau, John, Slater, Jerry, Daly, Mary B., Benson, Al B., Kirkwood, John M., O'Dwyer, Peter J., Sutphen, Rebecca, Stewart, James A., Johnson, David, Nordborg, Magnus, Krontiris, Theodore G.
Publicado 2008

DWI Metrics Differentiating Benign Intraductal Papillary Mucinous Neoplasms from Invasive Pancreatic Cancer: A Study in GEM Models

por Romanello Joaquim, Miguel, Furth, Emma E., Fan, Yong, Song, Hee Kwon, Pickup, Stephen, Cao, Jianbo, Choi, Hoon, Gupta, Mamta, Cao, Quy, Shinohara, Russell, McMenamin, Deirdre, Clendenin, Cynthia, Karasic, Thomas B., Duda, Jeffrey, Gee, James C., O’Dwyer, Peter J., Rosen, Mark A., Zhou, Rong
Publicado 2022

Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

por De Jesus-Acosta, Ana, Sugar, Elizabeth A., O’Dwyer, Peter J., Ramanathan, Ramesh K., Von Hoff, Daniel D., Rasheed, Zeshaan, Zheng, Lei, Begum, Asma, Anders, Robert, Maitra, Anirban, McAllister, Florencia, Rajeshkumar, N. V., Yabuuchi, Shinichi, de Wilde, Roeland F., Batukbhai, Bhavina, Sahin, Ismet, Laheru, Daniel A.
Publicado 2019

Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)

por Kemeny, M. Margaret, Zhao, Fengmin, Forastiere, Arlene A., Catalano, Paul, Hamilton, Stanley R., Miedema, Brent W., Dawson, Nancy A., Weiner, Louis M., Smith, Brian D., Mason, Bernard A., Graziano, Stephen L., Gilman, Paul B., Venook, Alan P., Pinto, Harlan A., Whitehead, Robert P., O’Dwyer, Peter J., Benson, Al B.
Publicado 2022

Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study

por Oh, Do-Youn, Maqueda, Maria Alsina, Quinn, David I., O’Dwyer, Peter J., Chau, Ian, Kim, Sun Young, Duran, Ignacio, Castellano, Daniel, Berlin, Jordan, Mellado, Begona, Williamson, Stephen K., Lee, Keun-Wook, Marti, Francisca, Mathew, Paul, Saif, Muhammad Wasif, Wang, Ding, Chong, Elizabeth, Hilger-Rolfe, Jacqueline, Dean, James P., Arkenau, Hendrik-Tobias
Publicado 2023